AngioDynamics has obtained an FDA green light for its NanoKnife prostate cancer ablation system, designed to precisely target ...

AngioDynamics has won US Food and Drug Administration (FDA) clearance for its NanoKnife system to be used in prostate cancer ...

AngioDynamics received FDA 510(k) clearance for its NanoKnife system for prostate tissue ablation in intermediate-risk ...

1 The study's results validated the robust safety and clinical efficacy profile of the NanoKnife System, reinforcing findings from more than 32 clinical studies performed around the world involving ...

AngioDynamics' latest regulatory approval is likely to pave the way for an alternative to conventional radical surgery and improve patient outcomes.

Shares of AngioDynamics hit a 52-week high after the company's NanoKnife System for prostate tissue ablation received regulatory clearance. The stock jumped almost 35% to a high of $9.42 in early ...

Published in Nature Communications, a new study led by the University of Minnesota Medical School and Duke University found ...

The following is a summary of “A digital and nurse-led support intervention, first year after prostate cancer treatment: a ...

Prostate cancer vaccines, including dendritic and peptide types, offer hope for improved treatments, but face hurdles in ...